Envafolimab plus chemo for stage III NSCLC before surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy (Envafolimab) combined with standard chemotherapy before and after surgery for stage III non-small cell lung cancer that can be removed. The goal is to see if adding Envafolimab helps shrink the tumor and improve outcomes compared to chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your lung cancer is stage IIIA or IIIB (N2) and doctors believe it can be surgically removed.
- You have not had any previous cancer treatment for this disease.
- Your cancer does not have certain genetic changes (EGFR or ALK) unless it's a specific cell type.
- You are healthy enough for surgery and have good organ and bone marrow function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests whether giving a combination of two immunotherapy drugs (ivonescimab or penpulimab) with chemotherapy before surgery helps shrink tumors and improve outcomes for people with early-stage non-small cell lung cancer. The goal is to make surgery more effective and reduce the chance of cancer coming back.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.